---
title: "ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strong"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293638677.md"
description: "Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T15:04:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293638677.md)
  - [en](https://longbridge.com/en/news/293638677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293638677.md)
generator: "portal-rs"
---

# ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strong

Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)

## Related News & Research

- [argenx (ENXTBR:ARGX) Hits A Phase 3 Win, Is The Upside Fully Priced?](https://longbridge.com/en/news/296529685.md)
- [ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3](https://longbridge.com/en/news/296061848.md)
- [RBC Capital Keeps Their Buy Rating on arGEN X (0QW0)](https://longbridge.com/en/news/296296197.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [argenex (NASDAQ:ARGX) Downgraded to "Hold" Rating by Deutsche Bank Aktiengesellschaft](https://longbridge.com/en/news/296805880.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**